Download PDF
Horm Metab Res 2023; 55(03): 205-211
DOI: 10.1055/a-2009-9629
Original Article: Endocrine Care

Long-Term Proton Pump Inhibitor Therapy and its Effect on Endocrine Hormones in Selected Patient Population

Muhammad Ashfaq
1   Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, COMSATS University Islamabad, Abbottabad, Pakistan
,
Qasim Khan
1   Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, COMSATS University Islamabad, Abbottabad, Pakistan
,
Muhammad Zeeshan Haroon
2   Department of Community Medicine, Ayub Medical College, Abbottabad, Pakistan
,
Syed Mobasher Ali Abid
1   Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, COMSATS University Islamabad, Abbottabad, Pakistan
,
Muhammad Junaid Hassan Sharif
1   Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, COMSATS University Islamabad, Abbottabad, Pakistan
,
Yasser MSA Alkahraman
1   Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, COMSATS University Islamabad, Abbottabad, Pakistan
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Proton pump inhibitors (PPI) are commonly prescribed medications for a variety of gastrointestinal disorders around the globe. Long-term utilization of proton pump inhibitors is linked with different adverse events. Although, short-term therapy has been demonstrated to have little or no impact on endocrine hormones in men, yet its safety with long-term use has poorly been studied. We aimed to evaluate the impacts of long-term utilization of proton pump inhibitors on male reproductive hormones and its clinical outcomes. A cross-sectional study was performed in two out-patients gastroenterology clinics in Khyber Pakhtunkhwa province. Male patients who were using PPIs regularly for≥3 months were enrolled in this study. Among 65 enrolled participants, patients with sexual complaints have significant variations in mean serum levels of prolactin (p<0.001), sex hormone binding globulins (p=0.043), total testosterone (p<0.001) and progesterone (p=0.001) as compared to patients without sexual complaints. Significantly high values of prolactin mean ranks were observed in patient with sexual complaints (p<0.001). There were statistically significant correlations of serum levels of sex hormone binding globulins (p=0.003), total testosterone (p=0.008) and progesterone (p<0.001) with serum prolactin levels. Similarly, statistically significant variation was observed for decreased libido (p=0.001), erectile dysfunction (p=0.001) and decreased semen mass ((p<0.001) between normal and hyperprolactinemic PPI users. Highly significant differences were observed in serum sex hormone binding globulins (p<0.001), total testosterone (p<0.001) and progesterone (p<0.001) values in normal and hyperprolactinemic groups. In conclusion, long-term utilization of PPI may induce endocrine hormone disruption with subsequent sexual complications.

Key words

proton pump inhibitors - long-term - endocrine hormones - sexual disorders - prolactin - testosterone


Publication History

Received: 25 August 2022

Accepted after revision: 10 January 2023

Accepted Manuscript online:
10 January 2023

Article published online:
14 February 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Sachs G, Shin JM, Howden CW. et al. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006; 23: 2-8
    CrossrefPubMedGoogle Scholar
  • 2 Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10: 528-534
    CrossrefPubMedGoogle Scholar
  • 3 Brett S. Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. Crit Care 2005; 9: 45-50
    CrossrefPubMedGoogle Scholar
  • 4 Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther 2013; 15: 1-6
    CrossrefPubMedGoogle Scholar
  • 5 Kyle C. A handbook for the interpretation of laboratory tests. Auckland: Diagnostic Medlab; 2008: 685
    Google Scholar
  • 6 Corona G, Isidori AM, Aversa A. et al. Endocrinologic control of men’s sexual desire and arousal/erection. J Sex Med 2016; 13: 317-337
    CrossrefPubMedGoogle Scholar
  • 7 Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci 2013; 6: 168-175
    CrossrefPubMedGoogle Scholar
  • 8 Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut Liver 2017; 11: 27-37
    CrossrefPubMedGoogle Scholar
  • 9 Wilhelm SM, Rjater RG, Kale-Pradhan PB. et al. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol 2013; 6: 443-451
    CrossrefPubMedGoogle Scholar
  • 10 Coulson M, Gibson GG, Plant N. et al. Lansoprazole increases testosterone metabolism and clearance in male Sprague-Dawley rats: implications for leydig cell carcinogenesis. Toxicol Appl Pharmacol 2003; 192: 154-163
    CrossrefPubMedGoogle Scholar
  • 11 García Rodríguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994; 308: 503-506
    CrossrefPubMedGoogle Scholar
  • 12 Thanoon IAJ, Mahmood AQ. Effect of omeprazole on reproductive hormonal levels and sexual function in male patients with peptic ulcer disease. Al-Qadisiyah Med J 2011; 7: 190-198
    PubMedGoogle Scholar
  • 13 Jabbar A, Khan R, Farrukh SN. Hyperprolactinaemia induced by proton pump inhibitor. JPMA J Pak Med Assoc 2010; 60: 689-690
    PubMedGoogle Scholar
  • 14 Pipaliya N, Solanke D, Rathi C. et al. Esomeprazole induced galactorrhea: a novel side effect. Clin J Gastroenterol 2016; 9: 13-16
    CrossrefPubMedGoogle Scholar
  • 15 Prieto OI, Alía EM, González AR. et al. Galactorrea inducida por lansoprazol. Aten Primaria 2004; 34: 325
    CrossrefPubMedGoogle Scholar
  • 16 Daniels IR, Layer GT. How should gynaecomastia be managed?. ANZ J Surg 2003; 73: 213-216
    CrossrefPubMedGoogle Scholar
  • 17 He B, Carleton B, Etminan M. Risk of gynecomastia with users of proton pump inhibitors. Pharmacother J Hum Pharmacol. Drug Ther 2019; 39: 614-618
    PubMedGoogle Scholar
  • 18 Arya R, Antonisamy B, Kumar S. et al. Sample size estimation in prevalence studies. Indian J Pediatr 2012; 79: 1482-1488
    CrossrefPubMedGoogle Scholar
  • 19 World Health Organization [WHO]. WHO guidelines on drawing blood: best practices in phlebotomy. World Health Organization; 2010
    Google Scholar
  • 20 Dammann HG, Bethke T, Burkhardt F. et al. Effects of pantoprazole on endocrine function in healthy male volunteers. Aliment Pharmacol Ther 1994; 8: 549-554
    CrossrefPubMedGoogle Scholar
  • 21 Dammann HG, Burkhardt F, Wolf N. et al. The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers. Aliment Pharmacol Ther 1999; 13: 1195-1203
    CrossrefPubMedGoogle Scholar
  • 22 MacGilchrist AJ, Howden CW, Kenyon CJ. et al. The effects of omeprazole on endocrine function in man. Eur J Clin Pharmacol 1987; 32: 423-425
    CrossrefPubMedGoogle Scholar
  • 23 Ni Lochlainn M, Kenny RA. Sexual activity and aging. J Am Med Dir Assoc 2013; 14: 565-572
    CrossrefPubMedGoogle Scholar
  • 24 Ashfaq M, Haroon MZ, Alkahraman YM. et al. Proton pump inhibitors therapy and risk of hyperprolactinemia with associated sexual disorders. Endocr Regul 2022; 56: 134-147
    CrossrefPubMedGoogle Scholar
  • 25 Ashfaq M, Abid SMA, Rauf K. et al. Potential role of proton pump inhibitors against human DRD2 receptor in drug-induced hyperprolactinemia. Rev Chim 2020; 71: 182-192
    CrossrefPubMedGoogle Scholar
  • 26 Plymate SR, Matej LA, Jones RE. et al. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988; 67: 460-464
    CrossrefPubMedGoogle Scholar
  • 27 Vermeulen A, Andó S, Verdonck L. et al. Prolactinomas, testosterone-binding globulin, and androgen metabolism. J Clin Endocrinol Metab 1982; 54: 409-412
    CrossrefPubMedGoogle Scholar
  • 28 Lobo RA, Kiletzky OA. Normalization of androgen and sex hormone-binding globulin levels after treatment of hyperprolactinemia. J Clin Endocrinol Metab 1983; 56: 562-566
    CrossrefPubMedGoogle Scholar
  • 29 Niwa T, Okamoto A, Narita K. et al. Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies. Arch Biochem Biophys 2020; 682: 108283
    CrossrefPubMedGoogle Scholar
  • 30 Quinney SK, Benjamin TD, Zheng X. et al. Characterization of maternal and fetal CYP3A-mediated progesterone metabolism. Fetal Pediatr Pathol 2017; 36: 400-411
    CrossrefPubMedGoogle Scholar
  • 31 Armstrong DT, Kraemer MA, Hixon JE. et al. Metabolism of progesterone by rat ovarian tissue: influence of pregnant mare serum gonadotropin and prolactin. Biol Reprod 1975; 12: 599-608
    CrossrefPubMedGoogle Scholar
  • 32 Kirino E. Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics. Ann Gen Psychiatry 2017; 16: 43
    CrossrefPubMedGoogle Scholar
  • 33 Montejo AL, Montejo L, Navarro-Cremades F. et al. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry 2015; 28: 418-423
    CrossrefPubMedGoogle Scholar
  • 34 Outhoff K. Antidepressant-induced sexual dysfunction: CPD. South Afr Fam Pract 2009; 51: 298-302
    CrossrefPubMedGoogle Scholar
  • 35 Lindquist M, Edwards IR. Endocrine adverse effects of omeprazole. BMJ 1992; 305: 451-452
    CrossrefPubMedGoogle Scholar
  • 36 Liu P, Yang S, Hao Y. et al. Evaluation of the irrational use of proton pump inhibitors and H-2 blockers among patients visited Chinese hospitals. Lat Am J Pharm 2020; 39: 836-841
    PubMedGoogle Scholar
  • 37 Rosenshein B, Flockhart DA, Ho H. et al. Induction of testosterone metabolism by esomeprazole in a CYP2C19*2 heterozygote. Am J Med Sci 2004; 327: 289-293
    CrossrefPubMedGoogle Scholar
  • 38 Amorós JG. Disfunción eréctil e inhibidores de la bomba de protones. Med Clínica 2000; 114: 478
    CrossrefPubMedGoogle Scholar
  • 39 Huijgen NA, de Ridder MAJ, Verhamme KM. et al. Are proton-pump inhibitors harmful to the semen quality of men in couples who are planning pregnancy?. Fertil Steril 2016; 106: 1666-1672.e2
    CrossrefPubMedGoogle Scholar
  • 40 Perry TW. Abrupt-onset, profound erectile dysfunction in a healthy young man after initiating over-the-counter omeprazole: a case report. J Med Case Reports 2021; 15: 1-3
    CrossrefPubMedGoogle Scholar
  • 41 Fass R, Fullerton S, Naliboff B. et al. Sexual dysfunction in patients with irritable bowel syndrome and non-ulcer dyspepsia. Digestion 1998; 59: 79-85
    CrossrefPubMedGoogle Scholar
  • 42 Park YE, Kim TO. Sexual dysfunction and fertility problems in men with inflammatory bowel disease. World J Mens Health 2020; 38: 285-297
    CrossrefPubMedGoogle Scholar